Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/46498
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDan H. Barouchen_US
dc.contributor.authorFrank L. Tomakaen_US
dc.contributor.authorFrank Wegmannen_US
dc.contributor.authorDaniel J. Stiehen_US
dc.contributor.authorGalit Alteren_US
dc.contributor.authorMerlin L. Robben_US
dc.contributor.authorNelson L. Michaelen_US
dc.contributor.authorLauren Peteren_US
dc.contributor.authorJoseph P. Nkololaen_US
dc.contributor.authorErica N. Borducchien_US
dc.contributor.authorAbishek Chandrashekaren_US
dc.contributor.authorDavid Jettonen_US
dc.contributor.authorKathryn E. Stephensonen_US
dc.contributor.authorWenjun Lien_US
dc.contributor.authorBette Korberen_US
dc.contributor.authorGeorgia D. Tomarasen_US
dc.contributor.authorDavid C. Montefiorien_US
dc.contributor.authorGlenda Grayen_US
dc.contributor.authorNicole Frahmen_US
dc.contributor.authorM. Juliana McElrathen_US
dc.contributor.authorLindsey Badenen_US
dc.contributor.authorJennifer Johnsonen_US
dc.contributor.authorJulia Hutteren_US
dc.contributor.authorEdith Swannen_US
dc.contributor.authorEtienne Karitaen_US
dc.contributor.authorHannah Kibuukaen_US
dc.contributor.authorJuliet Mpendoen_US
dc.contributor.authorNigel Garretten_US
dc.contributor.authorKathy Mngadien_US
dc.contributor.authorKundai Chinyenzeen_US
dc.contributor.authorFrances Priddyen_US
dc.contributor.authorErica Lazarusen_US
dc.contributor.authorFatima Laheren_US
dc.contributor.authorSorachai Nitayapanen_US
dc.contributor.authorPunnee Pitisuttithumen_US
dc.contributor.authorStephan Barten_US
dc.contributor.authorThomas Campbellen_US
dc.contributor.authorRobert Feldmanen_US
dc.contributor.authorGregg Lucksingeren_US
dc.contributor.authorCaroline Borremansen_US
dc.contributor.authorKatleen Callewaerten_US
dc.contributor.authorRaphaele Rotenen_US
dc.contributor.authorJerald Sadoffen_US
dc.contributor.authorLorenz Scheppleren_US
dc.contributor.authorMo Weijtensen_US
dc.contributor.authorKarin Feddes-de Boeren_US
dc.contributor.authorDaniëlle van Manenen_US
dc.contributor.authorJessica Vreugdenhilen_US
dc.contributor.authorRoland Zahnen_US
dc.contributor.authorLudo Lavreysen_US
dc.contributor.authorSteven Nijsen_US
dc.contributor.authorJeroen Tolboomen_US
dc.contributor.authorJenny Hendriksen_US
dc.contributor.authorZelda Euleren_US
dc.contributor.authorMaria G. Pauen_US
dc.contributor.authorHanneke Schuitemakeren_US
dc.contributor.otherJanssen Vaccines & Prevention B.V.en_US
dc.contributor.otherCentre for the AIDS Programme of Research in South Africaen_US
dc.contributor.otherInternational AIDS Vaccine Initiativeen_US
dc.contributor.otherMakerere Universityen_US
dc.contributor.otherJanssenen_US
dc.contributor.otherMassachusetts Institute of Technologyen_US
dc.contributor.otherMiami Research Associatesen_US
dc.contributor.otherNational Institute of Allergy and Infectious Diseasesen_US
dc.contributor.otherBrigham and Women's Hospitalen_US
dc.contributor.otherUniversity of Witwatersranden_US
dc.contributor.otherHJFen_US
dc.contributor.otherWalter Reed Army Institute of Researchen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherUniversity of Colorado at Denveren_US
dc.contributor.otherDuke Universityen_US
dc.contributor.otherLos Alamos National Laboratoryen_US
dc.contributor.otherRoyal Thai Armyen_US
dc.contributor.otherFred Hutchinson Cancer Research Centeren_US
dc.contributor.otherHarvard Medical Schoolen_US
dc.contributor.otherUniversity of Massachusetts Medical Schoolen_US
dc.contributor.otherOptimal Research LLCen_US
dc.contributor.otherTekton Researchen_US
dc.contributor.otherJanssen Infectious Diseasesen_US
dc.contributor.otherRwanda Zambia HIV Research Groupen_US
dc.date.accessioned2019-08-23T11:52:40Z-
dc.date.available2019-08-23T11:52:40Z-
dc.date.issued2018-07-21en_US
dc.identifier.citationThe Lancet. Vol.392, No.10143 (2018), 232-243en_US
dc.identifier.issn1474547Xen_US
dc.identifier.issn01406736en_US
dc.identifier.other2-s2.0-85053156358en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85053156358&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/46498-
dc.description.abstract© 2018 Elsevier Ltd Background: More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been the lack of direct comparability between clinical trials and preclinical studies. We aimed to evaluate mosaic adenovirus serotype 26 (Ad26)-based HIV-1 vaccine candidates in parallel studies in humans and rhesus monkeys to define the optimal vaccine regimen to advance into clinical efficacy trials. Methods: We conducted a multicentre, randomised, double-blind, placebo-controlled phase 1/2a trial (APPROACH). Participants were recruited from 12 clinics in east Africa, South Africa, Thailand, and the USA. We included healthy, HIV-1-uninfected participants (aged 18–50 years) who were considered at low risk for HIV-1 infection. We randomly assigned participants to one of eight study groups, stratified by region. Participants and investigators were blinded to the treatment allocation throughout the study. We primed participants at weeks 0 and 12 with Ad26.Mos.HIV (5 × 1010 viral particles per 0·5 mL) expressing mosaic HIV-1 envelope (Env)/Gag/Pol antigens and gave boosters at weeks 24 and 48 with Ad26.Mos.HIV or modified vaccinia Ankara (MVA; 108 plaque-forming units per 0·5 mL) vectors with or without high-dose (250 μg) or low-dose (50 μg) aluminium adjuvanted clade C Env gp140 protein. Those in the control group received 0·9% saline. All study interventions were administered intramuscularly. Primary endpoints were safety and tolerability of the vaccine regimens and Env-specific binding antibody responses at week 28. Safety and immunogenicity were also assessed at week 52. All participants who received at least one vaccine dose or placebo were included in the safety analysis; immunogenicity was analysed using the per-protocol population. We also did a parallel study in rhesus monkeys (NHP 13-19) to assess the immunogenicity and protective efficacy of these vaccine regimens against a series of six repetitive, heterologous, intrarectal challenges with a rhesus peripheral blood mononuclear cell-derived challenge stock of simian-human immunodeficiency virus (SHIV-SF162P3). The APPROACH trial is registered with ClinicalTrials.gov, number NCT02315703. Findings: Between Feb 24, 2015, and Oct 16, 2015, we randomly assigned 393 participants to receive at least one dose of study vaccine or placebo in the APPROACH trial. All vaccine regimens demonstrated favourable safety and tolerability. The most commonly reported solicited local adverse event was mild-to-moderate pain at the injection site (varying from 69% to 88% between the different active groups vs 49% in the placebo group). Five (1%) of 393 participants reported at least one grade 3 adverse event considered related to the vaccines: abdominal pain and diarrhoea (in the same participant), increased aspartate aminotransferase, postural dizziness, back pain, and malaise. The mosaic Ad26/Ad26 plus high-dose gp140 boost vaccine was the most immunogenic in humans; it elicited Env-specific binding antibody responses (100%) and antibody-dependent cellular phagocytosis responses (80%) at week 52, and T-cell responses at week 50 (83%). We also randomly assigned 72 rhesus monkeys to receive one of five different vaccine regimens or placebo in the NHP 13-19 study. Ad26/Ad26 plus gp140 boost induced similar magnitude, durability, and phenotype of immune responses in rhesus monkeys as compared with humans and afforded 67% protection against acquisition of SHIV-SF162P3 infection (two-sided Fisher's exact test p=0·007). Env-specific ELISA and enzyme-linked immunospot assay responses were the principal immune correlates of protection against SHIV challenge in monkeys. Interpretation: The mosaic Ad26/Ad26 plus gp140 HIV-1 vaccine induced comparable and robust immune responses in humans and rhesus monkeys, and it provided significant protection against repetitive heterologous SHIV challenges in rhesus monkeys. This vaccine concept is currently being evaluated in a phase 2b clinical efficacy study in sub-Saharan Africa (NCT03060629). Funding: Janssen Vaccines & Prevention BV, National Institutes of Health, Ragon Institute of MGH, MIT and Harvard, Henry M Jackson Foundation for the Advancement of Military Medicine, US Department of Defense, and International AIDS Vaccine Initiative.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85053156358&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleEvaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)en_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.1016/S0140-6736(18)31364-3en_US
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.